Cresco Labs

Cresco Labs has acquired PharmaCann Penn for $50 million, gaining nine operational medical marijuana dispensaries in Pennsylvania. The payment was made in cash and via a seller note on a debt- and cash-free basis with a normalized target working capital level. Cresco expects the transaction to boost revenue, margins and cash flow and now operates in the state as both a retail and wholesale operator, running dispensaries under the Sunnyside brand and maintaining cultivation and wholesale activities. » More on de.investing.com

Cresco Labs reported Q2 2026 revenue of $173.34 million and adjusted EPS of -$0.01, with both metrics topping analyst expectations. Adjusted EBITDA rose to $40 million (23% margin) and adjusted gross profit was $89 million (52% margin), while operating cash flow amounted to $15 million. The stock is trading near its 52-week low as investors weigh continued negative earnings, a only flat outlook for Q3 (around $173 million in revenue) and persistent pressures in the cannabis sector. Management sees growth potential in Pennsylvania, Ohio and Kentucky and a positive impact from possible federal reform, but warns of risks from competition, pricing pressure and regulatory uncertainty. » More on de.investing.com

Cresco Labs will report results for the quarter ended March 31, 2026, on May 8, 2026. Four analysts on average estimate a loss of -0.023 USD per share (prior year -0.060 CAD), and six analysts forecast revenue of about 148.9 million USD (prior year 237.8 million CAD). For the current fiscal year, median analyst expectations are a loss of -0.075 USD per share and revenue of about 620.8 million USD (prior year 916.4 million CAD). » More on finanzen.net